What is eHealth and why is it relevant to cardiology today? Watch videos and case studies and read the latest science on this hot topic
The ESC is involved in a number of EU funded research projects, often as a dissemination partner. Our role is fundamental to ensuring the very latest scientific best practice is shared with as many cardiovascular practitioners, researchers and institutions as possible.
Characterising Atrial Fibrilation by Translating its Causes into Health Modifiers in the Elderly (CATCH ME) brings together the expertise of leading academic institutes, healthcare organisations and professional societies to improve the care of patients with Atrial Fibrillation.
This is a Horizon 2020 funded project.
The objective of the BETA 3_LHV project to prevent patients having a structural heart remodelling and therefore at risk, to develop a heart failure.
The project is a clinical trial with an already marketed drug, known to be effective in bladder disorders that will be administered to patients in a new indication.
The aim of BigData@Heart is to improve patient outcomes and reduce the societal burden of heart failure, atrial fibrilation and acute coronary syndrome (ACS) in Europe.
BigData@Heart’s ultimate ambition is to unlock the societal, scientific, clinical and industrial value of current and future European data sets by fully realising the potential big data approaches have for cardiovascular diseases.
This is an Innovative Medicines Initiatives (IMI) funded project.
In this project, leading European scientific teams which have created large relevant population cohorts, mostly dedicated to Sundden Cardiac Arrest (SCA) research, join forces to fully exploit available data towards improving SCA management. This will be done by:
PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach for Chronic aortic aneurysms can reduce paraplegia and mortality dramatically.
It can be expected to have both a dramatic impact on the individual patient's quality of life if saved from a wheelchair and also upon financial systems through savings in:
Some 2 500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.
Cardioscape aims to outline the current Cardiovascular Diseases (CVD) research and innovation landscape across Europe.
ESC will not participate in projects for endorsement purposes only.
Only projects related to the ESC mission statement and ESC strategic orientations will be considered. This includes of course Working groups, Councils and Associations.
The final decision will be taken by ESC leadership.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved